Last Updated: September 24, 2026

Details for New Drug Application (NDA): 022110

✉ Email this page to a colleague

NDA 022110 describes VIBATIV, which is a drug marketed by Apotex and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the VIBATIV profile page.

The generic ingredient in VIBATIV is telavancin hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

Summary for 022110

Tradename:	VIBATIV
Applicant:	Apotex
Ingredient:	telavancin hydrochloride
Patents:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 022110

Generic Entry Date for 022110^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 7,531,623 Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022110

Suppliers and Packaging for NDA: 022110

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110	NDA	Cumberland Pharmaceuticals Inc.	66220-315	66220-315-11	1 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-11) / 50 mL in 1 VIAL, SINGLE-DOSE
VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110	NDA	Cumberland Pharmaceuticals Inc.	66220-315	66220-315-22	12 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-22) / 50 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INTRAVENOUS			Strength	EQ 250MG BASE/VIAL
Approval Date:	Sep 11, 2009	TE:		RLD:	Yes
Patent:	7,531,623	Patent Expiration:	Jan 1, 2027	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	EQ 750MG BASE/VIAL
Approval Date:	Sep 11, 2009	TE:		RLD:	Yes
Patent:	7,531,623	Patent Expiration:	Jan 1, 2027	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 022110

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apotex	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	7,008,923	⤷ Start Trial
Apotex	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	6,635,618	⤷ Start Trial
Apotex	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	7,700,550	⤷ Start Trial
Apotex	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	8,101,575	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.